Company Filing History:
Years Active: 2022
Title: The Innovations of Patrik Nygren
Introduction
Patrik Nygren is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting human α-synuclein aggregates. His work is crucial in understanding and potentially treating neurodegenerative diseases.
Latest Patents
Patrik Nygren holds a patent for α-synuclein protofibril-binding antibodies. This patent is based on the discovery of antibodies that selectively target human α-synuclein aggregates, such as oligomers and protofibrils. One of the key antibodies he developed is BAN0805, which has a lower tendency to bind to the undesired monomeric α-synuclein target compared to the mouse monoclonal antibody mAb47. This innovation could pave the way for new therapeutic approaches in treating conditions like Parkinson's disease.
Career Highlights
Nygren is associated with Bioarctic AB, a company focused on developing innovative treatments for neurodegenerative diseases. His work at Bioarctic has positioned him as a key player in the biotechnology sector, contributing to advancements that could significantly impact patient care.
Collaborations
Patrik collaborates with talented professionals, including Eva Nordström and Jessica Sigvardson. Their combined expertise enhances the research and development efforts at Bioarctic, fostering an environment of innovation and discovery.
Conclusion
Patrik Nygren's contributions to the field of biotechnology, particularly through his patent on α-synuclein protofibril-binding antibodies, highlight his role as an influential inventor. His work continues to inspire advancements in the treatment of neurodegenerative diseases.